A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism
J.R. Moskal, J. Burgdorf, R.A. Kroes, S.M. Brudzynski, J. Panksepp
· 2011
★ NIFPlay Rating: 8
Rating Scale
10 Rigorous play-specific science
6–9 General biological science
5 Sound play research (uncontrolled)
1–4 Less rigorous / indirect
0 Indirect but high value
Investigates the role of NMDA receptor modulation in social play vocalizations in rats, exploring GLYX-13 as a potential treatment for autism spectrum disorder.
